Dupilumab (Dupixent) is a fully human monoclonal antibody against the interleukin-4 receptor alpha (IL-4rα) subunit. Dupilumab inhibits signaling of type 2 cytokines IL-4 and IL-13 and is a therapeutic agent for atopic or allergic diseases. IL-4 and IL-13 mediated inflammation is an important part of the pathogenesis of asthma, atopic dermatitis, chronic sinusitis with nasal polyps, eosinophilic esophagitis and nodular pruritis. The use of dupriumab to block IL-4Rα can inhibit the inflammatory response induced by IL-4 and IL-13 cytokines. Dupilumab is currently available to treat asthma and nasal polyposis, as well as atopic dermatitis in pediatric patients. It can also be used in the treatment of eosinophilic esophagitis.
